Basket

You have nothing in your cart

Reader Domains

Reader Domains

Protein domains that bind to epigenetic modifications.

Product and Clone Results

Total results found: 98
Results per page: 102550100All
Catalogue No. Description Quantity Buy Now

ABE5765
I-BET151

A BET bromodomain inhibitor that interacts with BRD4 and BRD3 BET proteins and displaces them from chromatin; displays highefficacy against human and murine MLL-fusion leukemic cell lines, through the induction of early cell cycle arrest and apoptosis

1 mg

£51.00

ABE5822
UNC 1215

Cell-permeable

1 mg

£51.00

ABE7895
UNC-669

UNC-669 is a small molecule nicotinamide derivative that acts asan antagonist of the MBT(Malignant Brain Tumor) domain, a family of methyl-lysine binding reader proteins

5 mg

£66.00

ABE7911
I-BET762

I-BET762 (GSK525762) is a highly potent, selective and cell-permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 (IC50 of -35 nM)

1 mg

£66.00

ABE9203
UNC2170

UNC-2170 is a micromolar ligand for the Methyl-lysine Binding Protein, 53BP1

5 mg

£113.00

ABE7616
UNC 1215

Cell-permeable

5 mg

£175.00

ABE5766
I-BET151

A BET bromodomain inhibitor that interacts with BRD4 and BRD3 BET proteins and displaces them from chromatin; displays highefficacy against human and murine MLL-fusion leukemic cell lines, through the induction of early cell cycle arrest and apoptosis

5 mg

£198.00

ABE7896
UNC-669

UNC-669 is a small molecule nicotinamide derivative that acts asan antagonist of the MBT(Malignant Brain Tumor) domain, a family of methyl-lysine binding reader proteins

25 mg

£260.00

ABE7912
I-BET762

I-BET762 (GSK525762) is a highly potent, selective and cell-permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 (IC50 of -35 nM)

5 mg

£260.00

ABE9204
UNC2170

UNC-2170 is a micromolar ligand for the Methyl-lysine Binding Protein, 53BP1

25 mg

£446.00

 

For further information and prices please contact us or call +44 (0)115 973 9012

©2017 Source BioScience. All rights reserved